374Water going-concern warning: cash at $266K
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
374Water Inc. (SCWO) reported third-quarter 2026 revenue of $658,129, versus $760,417 a year earlier, and net loss of $3,261,209 versus $4,349,024. For the first nine months, revenue was $3,471,324, compared with $1,898,484, and net loss was $10,529,067, compared with $12,627,886. Equipment revenue was $2,047,001 and service revenue was $1,424,323; three customers generated approximately 90% of nine-month revenue.
At September 30, 2026, cash was $266,116, and operating activities used $4,154,268 in the first nine months. Management said these conditions raise substantial doubt about continuing as a going concern and that additional debt or equity financing is needed to continue operations and meet obligations for at least 12 months after issuance. It expects ongoing losses and negative operating cash flows until it can manufacture AirSCWO units commercially. Convertible-note principal was $3,532,500, bearing 10% interest and due three years from issuance. Holders waived any default related to unpaid September interest and elected to defer or convert it; no default existed as of the report date.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month revenue reached $3,471,324, versus $1,898,484 in 2025.
- Moderate pointNine-month net loss narrowed to $10,529,067 from $12,627,886.
Negative
- Major pointCash was $266,116 at September 30, 2026; management cited substantial doubt about continuing as a going concern.
- Moderate pointThird-quarter revenue declined 13% year over year.
Filing Explained
Amended notes increased potential share issuance and are secured by substantially all assets; the fifty-million-dollar ATM is a ceiling, not the sales reported.
This unaudited quarterly report says 374Water still needs debt or equity financing; its amended notes carry potential share issuance and are secured by substantially all company assets.
For
The sales agreement allows up to
After September 30, 374Water also issued five convertible notes totaling
Key Figures
Key Terms
supercritical water oxidation technical
AirSCWO technical
per- and polyfluoroalkyl substances technical
variable consideration financial
Black-Scholes option pricing model financial
baby shelf regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did SCWO report for the first nine months of 2026?
What are the terms of SCWO's convertible notes?
How much can SCWO sell under its ATM agreement?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form
For the Quarterly Period ended
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | |
| |
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Commission file No.

(Exact name of Registrant as specified in its charter) |
| ||
(State or other jurisdiction of incorporation or organization) |
| (IRS Employer Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
☒ | Smaller reporting company | ||
|
| Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: At November 13, 2026, the issuer had
Index to Form 10-Q
|
|
| Page |
|
PART I | FINANCIAL INFORMATION |
|
|
|
Item 1. | Condensed Consolidated Financial Statements (Unaudited) |
| 4 |
|
| Condensed Consolidated Balance Sheets at September 30, 2026 (Unaudited) and December 31, 2025 |
| 4 |
|
| Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 (Unaudited) |
| 5 |
|
| Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2026 and 2025 (Unaudited) |
| 6 |
|
| Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 (Unaudited) |
| 8 |
|
| Notes to Unaudited Condensed Consolidated Financial Statements |
| 9 |
|
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
| 26 |
|
Item 3. | Quantitative and Qualitative Disclosures about Market Risk |
| 31 |
|
Item 4. | Controls and Procedures |
| 31 |
|
|
|
|
|
|
PART II | OTHER INFORMATION |
|
|
|
Item 1. | Legal Proceedings |
| 32 |
|
Item 1A. | Risk Factors |
| 32 |
|
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |
| 32 |
|
Item 3. | Defaults upon Senior Securities |
| 32 |
|
Item 4. | Mine Safety Disclosures |
| 32 |
|
Item 5. | Other Information |
| 32 |
|
Item 6. | Exhibits |
| 33 |
|
|
|
|
|
|
SIGNATURES |
| 34 | ||
| 2 |
| Table of Contents |
Cautionary Note Regarding Forward-Looking Statements
Readers are cautioned that the statements in this Quarterly Report on Form 10-Q (this “Form 10-Q”) that are not descriptions of historical facts may be “forward-looking statements” that are subject to risks and uncertainties. This Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are based on the beliefs of our management, as well as on assumptions made by and information currently available to us as of the date of this Form 10-Q. When used in this Form 10-Q, the words “plan,” “will,” “may,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “project” and similar expressions are intended to identify such forward-looking statements. Although we believe these statements are reasonable, actual actions, operations and results could differ materially from those indicated by such forward-looking statements as a result of certain risks and uncertainties, including, but not limited to: changes in political and economic conditions; interest rate fluctuation; competitive pricing pressures within the Company’s market; equity and fixed income market fluctuation; technological changes; changes in law; changes in fiscal, monetary, regulatory, and tax policies; monetary fluctuations as well as the risk factors included in our 2025 Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026 (the “2025 Form 10-K”), and other risks and uncertainties detailed elsewhere in this Form 10-Q. We must caution, however, that this list of factors may not be exhaustive and that these or other factors, many of which are outside of our control, could have a material adverse effect on us and our ability to achieve our objectives. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above.
| 3 |
| Table of Contents |
PART I – FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
374Water Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
September 30, 2026 (Unaudited) and December 31, 2025
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Assets |
|
|
|
|
|
| ||
Current Assets: |
|
|
|
|
|
| ||
Cash |
| $ |
|
| $ |
| ||
Accounts receivable, net of credit allowance |
|
|
|
|
|
| ||
Other accounts receivable |
|
|
|
|
|
| ||
Unbilled accounts receivable |
|
|
|
|
|
| ||
Inventory, net |
|
|
|
|
|
| ||
Contract assets |
|
|
|
|
|
| ||
Prepaid expenses |
|
|
|
|
|
| ||
Total Current Assets |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
|
|
|
| ||
Intangible asset, net |
|
|
|
|
|
| ||
Right-of-use asset, net |
|
|
|
|
|
| ||
Other assets |
|
|
|
|
|
| ||
Total Long-Term Assets |
|
|
|
|
|
| ||
Total Assets |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
| $ |
|
| $ |
| ||
Accrued bonuses |
|
|
|
|
|
| ||
Accrued contract loss provision |
|
|
|
|
|
| ||
Unearned revenue |
|
|
|
|
|
| ||
Notes payable |
|
|
|
|
|
| ||
Secured promissory note |
|
|
|
|
|
| ||
Financing liability |
|
|
|
|
|
| ||
Operating lease liabilities |
|
|
|
|
|
| ||
Other liabilities |
|
|
|
|
|
| ||
Total Current Liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Unearned revenue, less current portion |
|
|
|
|
|
| ||
Notes payable, less current portion |
|
|
|
|
|
| ||
Convertible notes payable, net of discount |
|
|
|
|
|
| ||
Operating lease liabilities, less current portion |
|
|
|
|
|
| ||
Total Long-Term Liabilities |
|
|
|
|
|
| ||
Total Liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Stockholders’ Equity |
|
|
|
|
|
|
|
|
Preferred Stock: |
|
|
|
|
|
| ||
Common stock: |
|
|
|
|
|
| ||
Additional paid-in capital |
|
|
|
|
|
| ||
Accumulated deficit |
|
| ( | ) |
|
| ( | ) |
Accumulated other comprehensive income |
|
|
|
|
|
| ||
Total Stockholders’ Equity |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Total Liabilities & Stockholders’ Equity |
| $ |
|
| $ |
| ||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 4 |
| Table of Contents |
374Water Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
For the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
Revenues |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Cost of revenues |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Gross margin |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Compensation and related expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Professional fees |
|
|
|
|
|
|
|
|
|
|
|
| ||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Loss from operations |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
| ( | ) |
|
|
|
|
| ( | ) |
|
|
| ||
Interest income |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Loss on debt extinguishment |
|
|
|
|
|
|
|
| ( | ) |
|
|
| |||
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total other income, net |
|
| ( | ) |
|
|
|
|
| ( | ) |
|
|
| ||
Net loss before income taxes |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for Income Taxes |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share (basic and diluted) |
| $ | ( | ) |
| $ | ( | )(i) |
| $ | ( | ) |
| $ | ( | )(i) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding - basic and diluted |
|
|
|
|
| (i) |
|
|
|
|
| (i) | ||||
| (i) | Adjusted for the effect of a 1-for-10 reverse stock split that became effective December 26, 2025 (see Note 1). |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 5 |
| Table of Contents |
374Water Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders’ Equity
For the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)
For the Three and Nine Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||
|
| Preferred Stock |
|
| Common Stock |
|
| Additional Paid-in |
|
| Accumulated |
|
| Other Comprehensive |
|
| Total Stockholders' |
| ||||||||||||||
|
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| Income |
|
| Equity |
| ||||||||
Balances, December 31, 2024 |
|
| - |
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| ||||||
Issuance of shares of common stock for services |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Accretion of stock-based compensation - options |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Accretion of stock-based compensation - restricted stock |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Issuance of shares of common stock for option exercise |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balances, March 31, 2025 |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
| ||||||
Issuance of shares of common stock for services |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Accretion of stock-based compensation - options |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Accretion of stock-based compensation - restricted stock |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Issuance of vested restricted common stock |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
| ||||||
Issuance of shares of common stock for cash, net of issuance costs |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balances, June 30, 2025 |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
| ||||||
Issuance of shares of common stock for services |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Accretion of stock-based compensation - options |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Accretion of stock-based compensation - restricted stock |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Issuance of vested restricted common stock |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
| ||||||
Issuance of shares of common stock for cash, net of issuance costs |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Warrant repurchase |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
| ( | ) | ||||
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balances, September 30, 2025 |
|
| - |
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| ||||||
| 6 |
| Table of Contents |
For the Three and Nine Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||
|
| Preferred Stock |
|
| Common Stock |
|
| Additional Paid-in |
|
| Accumulated |
|
| Other Comprehensive |
|
| Total Stockholders' |
| ||||||||||||||
|
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| Income |
|
| Equity |
| ||||||||
Balance at December 31, 2025 |
|
| - |
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| ||||||
Issuance of shares of common stock for services |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Accretion of stock-based compensation - options |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Accretion of stock-based compensation - restricted stock |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Issuance of restricted common stock to executives and employees |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
| ||||||
Issuance of shares of common stock for cashless stock option exercises |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
| ||||||
Warrants issued with convertible promissory notes |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balances, March 31, 2026 |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
| ||||||
Issuance of shares of common stock for services |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Accretion of stock-based compensation - options |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Accretion of stock-based compensation - restricted stock |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Issuance of restricted common stock to executives and employees |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
| ||||||
Issuance of shares of common stock for stock option exercises |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Warrants issued with convertible promissory notes |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Warrant modification in connection with convertible debt amendment |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balances, June 30, 2026 |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
| ||||||
Issuance of shares of common stock for services |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Accretion of stock-based compensation - options |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Accretion of stock-based compensation - restricted stock |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Issuance of restricted common stock to executives and employees |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
|
|
|
|
| ||||||
Warrants issued with convertible promissory notes |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Warrant issued as settlement |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Sale of shares through at-the-market offering, net of issuance costs |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balances, September 30, 2026 |
|
| - |
|
| $ |
|
|
|
|
| $ |
|
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| ||||||
Common share amounts for 2025 have been retrospectively adjusted for the 1-for-10 Reverse Stock Split effective December 26, 2025 (see Note 1).
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 7 |
| Table of Contents |
374Water Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2026 and 2025 (Unaudited)
|
| Nine Months Ended September 30, |
| |||||
|
| 2026 |
|
| 2025 |
| ||
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
| ||
Net loss |
| $ | ( | ) |
| $ | ( | ) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
| ||
Amortization of debt discount |
|
|
|
|
|
| ||
Non-cash lease expense |
|
|
|
|
|
| ||
Issuance of common stock for services |
|
|
|
|
|
| ||
Stock-based compensation |
|
|
|
|
|
| ||
Loss on debt extinguishment |
|
|
|
|
|
| ||
Warrants issued in settlement |
|
|
|
|
|
| ||
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
| ( | ) | |
Unbilled accounts receivable |
|
| ( | ) |
|
| ( | ) |
Other receivables |
|
| ( | ) |
|
|
| |
Inventory |
|
| ( | ) |
|
| ( | ) |
Contract assets |
|
|
|
|
| ( | ) | |
Prepaid expenses |
|
|
|
|
|
| ||
Other assets |
|
|
|
|
| ( | ) | |
Accounts payable and accrued expenses |
|
|
|
|
|
| ||
Accrued bonuses |
|
|
|
|
| ( | ) | |
Accrued contract loss provision |
|
|
|
|
|
| ||
Accrued legal settlement |
|
|
|
|
| ( | ) | |
Unearned revenue |
|
|
|
|
|
| ||
Other liabilities |
|
|
|
|
|
| ||
Operating lease liabilities |
|
| ( | ) |
|
| ( | ) |
Net cash used in operating activities |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
Net cash used in investing activities |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Repayments on notes payable |
|
| ( | ) |
|
| ( | ) |
Repayments on financing liabilities |
|
| ( | ) |
|
| ( | ) |
Proceeds from (repayments of) secured promissory notes |
|
| ( | ) |
|
|
| |
Proceeds from the issuance of convertible notes payable |
|
|
|
|
|
| ||
Proceeds from the sale of common stock, net of issuance costs |
|
|
|
|
|
| ||
Proceeds from the exercise of common stock options |
|
|
|
|
|
| ||
Warrant repurchase |
|
|
|
|
| ( | ) | |
Net cash provided by financing activities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of period |
| $ |
|
| $ |
| ||
Cash and cash equivalents, end of period |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
Supplemental cash flow disclosures |
|
|
|
|
|
|
|
|
Cash paid for interest |
| $ |
|
| $ |
| ||
Cash paid for taxes |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
Supplemental disclosure of non-cash investing and financing activities |
|
|
|
|
|
|
|
|
Common stock sold with subscription receivables, net of issuance costs |
| $ |
|
| $ |
| ||
Equipment financed with a note payable |
| $ |
|
| $ |
| ||
Issuance of restricted common stock to executives and employees |
| $ |
|
| $ |
| ||
Prepaid insurance financed |
| $ |
|
| $ |
| ||
Recognition of ROU asset and operating lease liabilities |
| $ |
|
| $ |
| ||
Shares of common stock issued for cashless stock option exercise |
| $ |
|
| $ |
| ||
Warrants issued with convertible notes payable |
| $ |
|
| $ |
| ||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 8 |
| Table of Contents |
374Water Inc. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements
Note 1 – Nature of Business and Presentation of Financial Statements
Description of the Company
374Water Inc. (the “Company”, “374Water”, “we”, or “our”) is a cleantech and environmental services company developing supercritical water oxidation (“SCWO”) for the destruction of organic waste streams within the municipal, federal, and industrial markets. 374Water offers our proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Importantly, our AirSCWO system is designed to eliminate recalcitrant organic wastes without creating waste byproducts, as well as to simplify existing, complex waste processing and disposal practices. Our AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including ‘forever chemicals’ (e.g., “per- and polyfluoroalkyl substances” or “PFAS”) into inert and recoverable resources including water, minerals, and heat energy.
At a special meeting of stockholders held on December 15, 2025, the stockholders of 374Water approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, to, at the discretion of the Company’s Board of Directors, effect a reverse stock split with respect to the Company’s issued and outstanding common stock, at a ratio of 1-for-8 to 1-for-20, with the ratio within such range to be determined at the discretion of the Company’s Board of Directors (or any of its delegated authorized persons) without further approval or authorization of our stockholders.
On December 15, 2025, after the approval from the stockholders, the Company filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock. The Certificate of Amendment took effect on December 26, 2025. All share and per share amounts have been retrospectively adjusted for the effect of the Reverse Stock Split.
Presentation of Financial Statements and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) for interim financial information. It is management’s opinion that the accompanying unaudited condensed consolidated financial statements are prepared in accordance with instructions for Form 10-Q and include all adjustments (consisting only of normal recurring accruals) which are necessary for a fair presentation of the results for the periods presented. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the Annual Report on Form 10-K of 374Water at and for the year ended December 31, 2025, filed with the SEC on March 31, 2026, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026 (the “2025 Form 10-K”).
The results of operations for the three and nine months ended September 30, 2026, are not necessarily indicative of the results to be expected for the full year or for future periods. The unaudited condensed consolidated financial statements include the accounts of 374Water Inc., 374Water Systems Inc., and 374Water Sustainability Israel LTD, currently inactive, each a wholly owned subsidiary of 374Water. Intercompany balances and transactions have been eliminated in consolidation.
| 9 |
| Table of Contents |
Note 2 – Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying consolidated financial statements include the fair value of equity-based compensation and warrants issued with convertible notes, revenue recognition, accrued loss provisions on onerous contracts, useful lives of long-lived assets, and the valuation allowance against deferred tax assets.
Accounts Receivable, Net
Accounts receivable due from customers are uncollateralized customer obligations due under normal and customary trade terms. Accounts receivable are stated at the amount billed to the customer, less an allowance for estimated credit losses.
Inventory, Net
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The majority of our inventory is raw materials. Net realizable value is the value of an asset that can be realized upon the sale of the asset, less a reasonable estimate of the costs associated with either the eventual sale or the disposal of the asset in question. Costs associated with fabrication, and other costs associated with the manufacturing of products, are recorded as inventory. We periodically evaluate the carrying value of our inventories in relation to estimated forecasts of product demand, which takes into consideration the life cycle of product releases. When quantities on hand exceed estimated sales or usage forecasts, we perform an analysis to determine if a write-down for such excess inventories is required. Once inventory has been written down, it creates a new cost basis for inventory. Inventories are classified as current assets in accordance with recognized industry practice. Based on our evaluation, we estimated an inventory allowance of $
Property and Equipment
Property and equipment are recorded at cost. Depreciation is computed using the straight-line method and the estimated useful life of the asset. Expenses for maintenance and repairs are charged to expense as incurred.
The following table presents property and equipment at September 30, 2026 and December 31, 2025:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Computers |
| $ |
|
| $ |
| ||
Equipment |
|
|
|
|
|
| ||
Equipment - Demo System |
|
|
|
|
|
| ||
Vehicles |
|
|
|
|
|
| ||
Equipment-in-process |
|
|
|
|
|
| ||
Total property and equipment |
|
|
|
|
|
| ||
Less: accumulated depreciation |
|
| ( | ) |
|
| ( | ) |
Total property and equipment, net |
| $ |
|
| $ |
| ||
| 10 |
| Table of Contents |
Depreciation expense is presented as follows in the unaudited condensed consolidated statement of operations:
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
Cost of revenues |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
General and administrative |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total depreciation expense |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, and marketable securities. Deposits with financial institutions are insured, up to certain limits, by the Federal Deposit Insurance Corporation (“FDIC”). The Company’s cash deposits often exceed the FDIC insurance limit; however, all deposits are maintained with high credit quality institutions and the Company has not experienced any losses in such accounts. The financial condition of financial institutions is periodically reassessed, and the Company believes the risk of any loss is minimal. Furthermore, we perform ongoing credit evaluations of our customers and generally do not require collateral.
Significant customers and suppliers are those that account for greater than
For the three and nine months ended September 30, 2026, we generated approximately
At September 30, 2026, two customers comprised approximately
Revenue Recognition
The Company follows the revenue standards of Accounting Standards Codification (“ASC”) Topic 606: “Revenue from Contracts with Customers (Topic 606).” The core principle of this Topic is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Revenue is recognized in accordance with that core principle by applying the following five steps: 1) identify the contracts with a customer; 2) identify the performance obligations in the contract; 3) determine the transaction price; 4) allocate the transaction price to the performance obligations; and 5) recognize revenue when (or as) we satisfy a performance obligation using the input method.
The Company generates revenue from providing waste destruction services, including the completion of full-scale demonstrations and treatability studies, and the sale of equipment (AirSCWO units) to customers. In the case of equipment revenues, the Company’s performance obligations are satisfied over time as the equipment is being manufactured and are typically long-term fixed price contracts. Revenue is recognized over time by measuring the progress toward complete satisfaction of the performance obligation based on an input method. Equipment sale-related revenues are recognized in the proportion that contract costs incurred bear to total estimated costs to be incurred to complete the equipment contract. The estimated completed percentage is applied to the total transaction price of the fixed price contract. This method is used because management considers the input method to be the best available measure of progress on these contracts.
| 11 |
| Table of Contents |
Changes in our overall expected cost estimates are recognized as a cumulative adjustment for the inception-to-date effect of such a change. If these changes in estimates result in a possible loss being incurred on the contract, we accrue for such a loss in the period such an outcome becomes probable.
Services revenues related to bench-scale treatability studies are recognized when all five revenue recognition criteria have been met, which is generally when we deliver a completed treatability study report to the customer.
Service revenues related to our full-scale demonstrations, using our owned AirSCWO unit, may include multiple performance obligations, typically the demonstration itself and a technical report that summarizes the analysis of materials processed. Management estimates are required in allocating the transaction price between the performance obligations. However, other full-scale demonstrations may include one performance obligation, the demonstration itself. Revenues from such contracts are recognized over time as the demonstration is being completed.
Olathe Contract
On March 4, 2026, we entered into a purchase order with Garney Companies, Inc. (“Garney”) in connection with the Cedar Creek Wastewater Treatment Plant Expansion Phase II project in Olathe, Kansas. Under the purchase order, the Company will design, fabricate, deliver, install, and commission an AirSCWO 6 supercritical water oxidation unit and related pretreatment, dewatering, and water treatment equipment, and will provide startup, training, and warranty services.
The principal terms of the purchase order are as follows:
| · | |
|
|
|
| · | Payment milestones: 50% upon contract execution; 20% upon delivery of SCWO equipment; 20% upon delivery of dewatering equipment; 5% upon successful startup and commissioning; and 5% upon final hand-over and customer acceptance, in each case net of 5% retainage withheld until final acceptance. |
|
|
|
| · | Warranty: Standard one-year warranty plus an additional one-year extended warranty for total coverage of 24 months from acceptance. |
| 12 |
| Table of Contents |
The purchase order also contains customary provisions regarding indemnification, insurance, change orders, and dispute resolution, and includes a buy-back provision under which the Company would offer a trade-in credit currently estimated at $
During the nine months ended September 30, 2026, we issued Garney an invoice totaling $
OC San Contract and Change in Accounting Estimate
Our equipment revenue contract with the Orange County Sanitation District (“OC San”) is a fixed price contract that includes billings based on the achievement of deliverables or milestones. During the year ended December 31, 2025, we had experienced delays in completing the equipment due to design changes and upgrades preventing us from meeting the next contractual milestone. Due to these delays, we had been contractually unable to bill for certain costs incurred related to the OC San contract. At December 31, 2025, we incurred costs in excess of billings of approximately $
Pursuant to the contract terms with OC San, we were unable to invoice and resume billing until the manufactured equipment passed a factory acceptance test (“FAT”) which is based on a continuous run time of the equipment and volume of materials processed. At contract inception, the variable consideration included in the contract price was not deemed to be constrained. We had anticipated delivering the equipment to OC San during the year ended December 31, 2025. Due to the unexpected delays we had encountered in delivering the equipment, we reassessed the variable consideration at December 31, 2025. The changes in facts and circumstances resulted in us fully constraining the variable consideration at December 31, 2025 and ceasing revenue recognition on this contract after the nine months ended September 30, 2025. This resulted in the reduction of unbilled accounts receivable and a reduction in equipment revenue in the amount of approximately $
At June 30, 2026, OC San approved a change order which resulted in the modification of metrics required to pass the FAT. Specifically, the volume of materials to be processed was reduced from 6 tons per day to 3.25 tons per day. Upon the passing of the FAT, the Company invoiced OC San in the amount of $
See further revenue-related disclosures in Note 6.
Contract costs include all direct material, labor and subcontractor costs and those indirect costs related to contract performance, such as indirect labor, supplies, tools, repairs, and depreciation.
Research and Development Costs
The Company’s research and development costs are expensed in the period in which they are incurred. Such expenditures amounted to $
| 13 |
| Table of Contents |
Loss Per Share
Loss per share is computed in accordance with ASC Topic 260, “Earnings per Share.” Basic weighted-average number of shares of common stock outstanding for the three and nine months ended September 30, 2026 and 2025 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be antidilutive. At September 30, 2026 and September 30, 2025, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their effect would be antidilutive: options for
Recent Accounting Pronouncements – Not Yet Adopted
Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (“DISE”). In November 2024, the FASB issued a new accounting standard to improve the disclosures about an entity’s expenses and address requests from investors for more detailed information about the types of expenses included in commonly presented expense captions. The new standard is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with retrospective application permitted. The Company is evaluating the disclosure requirements related to the new standard and its impact on our consolidated financial statements.
The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.
Note 3 – Liquidity, Capital Resources and Going Concern
In accordance with ASU No. 2014-15 Presentation of Financial Statements – Going Concern (subtopic 205-40), the Company’s management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. At September 30, 2026, the Company had a working capital of $
Presently, the Company will need additional debt or equity financing or a combination of both to continue its operations and meet its financial obligations for at least the next twelve months from the date these unaudited condensed interim consolidated financial statements were issued and beyond. We may consume available resources more rapidly than currently anticipated, resulting in the need for additional funding. We expect to incur continuing losses and negative cash flows from operations for the foreseeable future until we are able to manufacture our AirSCWO units on a commercial scale.
We have entered into an at-the-market sales agreement (“ATM”), dated August 10, 2026 with Roberts & Ryan Inc. relating to shares of our common stock (the “Sales Agreement”). In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock, par value $0.0001 per share, having an aggregate offering price of up to $50,000,000 from time to time through Roberts & Ryan, acting as our sales agent.
This Sales Agreement replaces our prior sales agreement, dated December 23, 2025 with Lake Street Capital Markets, LLC (“Lake Street”) (the “Prior Sales Agreement”) which replaced a prior sales agreement executed with Lake Street on June 6, 2025. The Company had no sales pursuant to the Prior Sales Agreement.
As of the date the prospectus was filed,
| 14 |
| Table of Contents |
Any additional debt or equity financing that the Company obtains may substantially dilute the ownership held by our existing stockholders. The economic dilution to our stockholders will be significant if our stock price does not materially increase, or if the effective price of any sale is below the price paid by a particular investor. The Company may be unable to access further equity or debt financing when needed or obtain additional financing under acceptable terms, if at all.
We may decide to raise additional capital through a variety of sources in the short-term and in the long-term, including but not limited to:
| ☐ | the public equity markets; |
| ☐ | private equity financings; |
| ☐ | collaborative arrangements; |
| ☐ | asset sales; and/or |
| ☐ | public or private debt. |
If the Company is unable to raise additional capital, there is a risk that the Company could be required to discontinue or significantly reduce the scope of its operations. These unaudited condensed interim consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Note 4 – Inventory, Net
Inventory, net consists of:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Raw materials |
| $ |
|
| $ |
| ||
Less: inventory reserve |
|
| ( | ) |
|
| ( | ) |
Total |
| $ |
|
| $ |
| ||
Note 5 – Debt
Obligations
Convertible Notes
During the nine months ended September 30, 2026, we issued an aggregate of $
| 15 |
| Table of Contents |
The aggregate incremental value from the Modification to the embedded conversion option exceeded 10% of the total outstanding principal on the modified convertible notes. Therefore, the Modification resulted in an extinguishment of debt pursuant to ASC 470-50-40-10(a). Pursuant to ASC 470-50 Modifications and Extinguishments, the Company remeasured the acquisition price of the debt based on the fair value of the replacement convertible notes which approximated its $
We computed the incremental value received by the convertible note holders due to the Modification of the conversion rate and warrant exercise price using a Black-Scholes option pricing model (the “Black-Scholes”) and the following inputs: expected term of approximately
At initial issuance of the $
Post Modification, an additional $
During the three and nine months ended September 30, 2026, we recognized $
At September 30, 2026, the total principal balance on the convertible notes is $3,532,500, which is due three years from issuance or March–September 2029, and accrued interest is $
Note Payable
During the year ended December 31, 2025, we purchased approximately $
During the three and nine months ended September 30, 2026, we purchased approximately $
| 16 |
| Table of Contents |
At September 30, 2026, future principal payments on the note payable for the years ending December 31, will be as follows:
Year Ending December 31, |
|
|
| |
2026 (remaining) |
| $ |
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 |
|
|
| |
Thereafter |
|
|
| |
Total |
| $ |
| |
Secured Promissory Note
On September 30, 2025, the Company executed a $
Financing Liability
During the year ended December 31, 2025, we entered into a financing agreement to finance $
Note 6 – Revenue
The following is a summary of our revenues by type for the three and nine months ended September 30, 2026 and September 30, 2025:
|
| Three Months Ended September 30, |
| |||||||||||||
|
| 2026 |
|
| % |
|
| 2025 |
|
| % |
| ||||
Equipment revenue |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Service revenue |
|
|
|
|
| % |
|
|
|
|
| % | ||||
Total |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
|
|
| ||||||||||||||
|
| Nine Months Ended September 30, | ||||||||||||||
|
| 2026 |
|
| % |
|
| 2025 |
|
| % |
| ||||
Equipment revenue |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Service revenue |
|
|
|
|
| % |
|
|
|
|
| % | ||||
Total |
| $ |
|
|
| % |
| $ |
|
|
| % | ||||
Unearned Revenue
The following is a summary of our unearned revenue activity for the nine months ended September 30, 2026 and year ended December 31, 2025:
|
| Balance at September 30, 2026 |
|
| Balance at December 31, 2025 |
| ||
Unearned revenue at beginning of the period |
| $ |
|
| $ |
| ||
Billings deferred |
|
|
|
|
|
| ||
Recognition of prior unearned revenue |
|
| ( | ) |
|
| ( | ) |
Unearned revenue at end of period |
| $ |
|
| $ |
| ||
| 17 |
| Table of Contents |
During the nine months ended September 30, 2026, we recognized $
Note 7 – Stockholders’ Equity
On September 30, 2026, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to (i) decrease the number of authorized shares of common stock of the Company from 1,000,000,000 shares to 75,000,000 shares and (ii) amend and restate Article Eight, Section A of the Company’s certificate of incorporation relating to the personal liability of directors and officers, in order to conform such provision to Section 102(b)(7) of the General Corporation Law of the State of Delaware.
As of September 30, 2026, the Company is authorized to issue
Preferred Stock
On October 30, 2020, the Company designated
Common Stock
Issuance of Stock for Services
During the nine months ended September 30, 2026, we issued
During the nine months ended September 30, 2025, we issued
Common Stock for Stock Option Exercises
During the nine months ended September 30, 2026, we issued an aggregate of
During the nine months ended September 30, 2025, we issued
Fully Vested Restricted Common Stock
During the nine months ended September 30, 2026, certain executives and key employees vested in time-based restricted stock resulting in the Company issuing
During the nine months ended September 30, 2025, certain executives and key employees vested in time-based restricted stock resulting in the Company issuing
Common Stock sold on the At-the-Market Offering
During the nine months ended September 30, 2026, we sold
During the nine months ended September 30, 2025, we sold
| 18 |
| Table of Contents |
Stock-based compensation
2021 Plan
The Company has reserved
Stock-based compensation expense related to the stock options and restricted stock units expected to vest is presented as follows on the condensed consolidated statements of operations:
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||||
Research and development |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Compensation and related expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
General and administrative expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total expense |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
A summary of stock option activity during the nine months ended September 30, 2026 is as follows:
|
| Shares |
|
| Weighted Average Exercise Price |
|
| Aggregate Intrinsic Value |
|
| Weighted Average Remaining Contractual Life (Years) |
| ||||
Options outstanding at December 31, 2025 |
|
|
|
| $ |
|
| $ |
|
|
|
| ||||
Granted |
|
| - |
|
|
|
|
|
| - |
|
|
|
| ||
Exercised |
|
| ( | ) |
|
|
|
|
| - |
|
|
|
| ||
Expired/forfeit |
|
| ( | ) |
|
|
|
|
| - |
|
|
| - |
| |
Options outstanding at March 31, 2026 |
|
| * |
| $ |
|
| $ |
|
|
|
| ||||
Granted |
|
|
|
|
|
|
|
| - |
|
|
| - |
| ||
Exercised |
|
| ( | ) |
|
|
|
|
| - |
|
|
| - |
| |
Expired/forfeit |
|
| ( | ) |
|
|
|
|
| - |
|
|
| - |
| |
Options outstanding at June 30, 2026 |
|
| * |
| $ |
|
| $ | - |
|
|
|
| |||
Granted |
|
|
|
|
|
|
|
| - |
|
|
| - |
| ||
Exercised |
|
| - |
|
|
|
|
|
| - |
|
|
| - |
| |
Expired/forfeit |
|
| ( | ) |
|
|
|
|
| - |
|
|
| - |
| |
Options outstanding at September 30, 2026 |
|
| * |
| $ |
|
| $ |
|
|
|
| ||||
Options exercisable at September 30, 2026 |
|
| * |
| $ |
|
| $ |
|
|
|
| ||||
*At September 30, 2026 and December 31, 2025, the options outstanding and exercisable include
Intrinsic value is based on the difference between the option exercise price and the quoted closing market price at September 30, 2026 or the date of option exercise.
During the nine months ended September 30, 2026, we granted our employees, our CEO and our Chief Financial Officer (“CFO”) stock options with exercise prices of $
Of the total options outstanding at September 30, 2026,
| 19 |
| Table of Contents |
At September 30, 2026, total unrecognized compensation expense for service-based and performance-based options was $
The weighted-average grant date fair value of the options granted during the nine months ended September 30, 2026 and September 30, 2025 was $
The grant date fair value was estimated using the Black-Scholes option pricing model during the nine months ended September 30, 2026 and 2025 and the following assumptions:
|
| September 30, 2026 |
|
| September 30, 2025 |
| ||
Expected volatility |
| % |
| % | ||||
Expected term (years) |
|
|
|
|
| |||
Risk-free rate |
| % |
| % | ||||
Dividend rate |
|
| % |
|
| % | ||
Restricted Stock Units (“RSUs”)
At September 30, 2026,
A summary of our outstanding unvested time-based RSUs during the nine months ended September 30, 2026 is as follows:
|
| Amount |
|
| Weighted-Average Grant Date Fair Value |
| ||
Unvested, December 31, 2025 |
|
|
|
| $ |
| ||
Vested |
|
| ( | ) |
|
|
| |
Forfeited |
|
| ( | ) |
|
|
| |
Unvested, March 31, 2026 |
|
|
|
| $ |
| ||
Granted |
|
|
|
|
|
| ||
Vested |
|
| ( | ) |
|
|
| |
Forfeited |
|
| ( | ) |
|
|
| |
Unvested, June 30, 2026 |
|
|
|
| $ |
| ||
Granted |
|
|
|
|
|
| ||
Vested |
|
| ( | ) |
|
|
| |
Forfeited |
|
| - |
|
|
|
| |
Unvested, September 30, 2026 |
|
|
|
| $ |
| ||
During the six months ended June 30, 2026, we granted our CEO
| 20 |
| Table of Contents |
A summary of our outstanding unvested performance-based RSUs during the nine months ended September 30, 2026 is as follows:
|
| Amount |
|
| Weighted-Average Grant Date Fair Value |
| ||
Unvested, December 31, 2025 |
|
|
|
| $ |
| ||
Forfeited |
|
| ( | ) |
|
|
| |
Unvested, March 31, 2026 |
|
|
|
| $ |
| ||
Unvested, June 30, 2026 |
|
| 141,895 |
|
| $ | 4.48 |
|
Unvested, September 30, 2026 |
|
| 141,895 |
|
| $ | 4.48 |
|
At September 30, 2026, we have $
Stock Warrants
A summary of warrant activity for the nine months ended September 30, 2026 is as follows:
|
| Shares |
|
| Weighted Average Exercise Price |
|
| Aggregate Intrinsic Value |
|
| Weighted Average Remaining Contractual Life (Years) |
| ||||
Warrants outstanding at December 31, 2025 |
|
|
|
| $ |
|
| $ |
|
|
|
| ||||
Granted |
|
|
|
|
|
|
|
|
|
|
| - |
| |||
Expired/forfeit |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
Warrants outstanding at March 31, 2026 |
|
|
|
| $ |
|
| $ |
|
|
|
| ||||
Granted |
|
|
|
|
|
|
|
|
|
|
| - |
| |||
Additional warrants due to Modification (Note 5) |
|
|
|
|
|
|
|
| - |
|
|
| - |
| ||
Expired/forfeit |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
Warrants outstanding at June 30, 2026 |
|
|
|
| $ | * |
| $ |
|
|
|
| ||||
Granted |
|
|
|
|
|
|
|
|
|
|
| - |
| |||
Expired/forfeit |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
Warrants outstanding at September 30, 2026 |
|
|
|
| $ | * |
| $ |
|
|
|
| ||||
Warrants exercisable at September 30, 2026 |
|
|
|
| $ | * |
| $ |
|
|
|
| ||||
*Weighted-average exercise price is after the reduction in exercise price for the Modification that occurred during the three months ended June 30, 2026 (see Note 5).
In connection with a release, strategic support and warrant issuance agreement executed with a stockholder on September 21, 2026, the Company issued
| 21 |
| Table of Contents |
Note 8 – Related Party Transactions
See Note 5 for a description of convertible notes issued to three non-employee directors during the nine months ended September 30, 2026 totaling $
See Note 7 for a description of a cashless option exercise by our current CEO during the nine months ended September 30, 2026 resulting in the issuance of
Note 9 – Commitments and Contingencies
Operating Leases
On January 26, 2026, the Company entered into a license agreement with the City of Orlando, Florida (the “Orlando License Agreement”). The Orlando License Agreement grants the Company a temporary, revocable, nonexclusive license to use approximately 15,000 square feet of the facility for the following: (i) installation and operation of AirSCWO units to process city wastewater sludge, (ii) processing of certain approved third-party materials under a Waste Destruction Service (“WDS”) program, subject to approval by the City of Orlando, (iii) maintenance of equipment, manufacturing of AirSCWO units and (iv) inventory storage. The initial term of the Orlando License Agreement commenced February 1, 2026 for a period of five years with two optional five-year renewal terms. In April 2026, an amendment was executed to the Orlando License Agreement for 21,639 additional square feet. The amendment is effective May 1, 2026. Monthly rent payments of $
The City of Orlando will also receive a WDS fee for any approved third-party materials that are processed at the facility based on the type of third-party materials processed which will be charged at a per pound or gallon rate depending on the type of material.
At the commencement of the Orlando License Agreement and upon execution of the April 2026 amendment, we recognized an aggregate right-of-use asset and operating lease liabilities of $
We also lease laboratory space in North Carolina under a lease agreement with a term of September 1, 2024 to October 1, 2029 with one five-year extension period. The extension period was not included in our initial present value of the right-of-use asset or operating lease liability as it was not reasonably certain the option would be exercised. Monthly rental payments required under the lease are subject to annual increases and range from $
Right-of-use assets are summarized below:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Right-of-use assets |
| $ |
|
| $ |
| ||
Accumulated amortization |
|
| ( | ) |
|
| ( | ) |
Right-of-use assets, net |
| $ |
|
| $ |
| ||
Operating lease liabilities are summarized below:
|
| September 30, 2026 |
|
| December 31, 2025 |
| ||
Operating lease liabilities, current |
| $ |
|
| $ |
| ||
Operating lease liabilities, less current portion |
|
|
|
|
|
| ||
Total operating lease liabilities |
| $ |
|
| $ |
| ||
| 22 |
| Table of Contents |
Future payments required on the operating lease liabilities, over a weighted-average term of approximately 3.87 years, are as follows:
Year Ending December 31, |
|
|
| |
2026 (remaining) |
| $ |
| |
2027 |
|
|
| |
2028 |
|
|
| |
2029 |
|
|
| |
2030 |
|
|
| |
Thereafter |
|
|
| |
Total |
| $ |
| |
Less: present value discount at a weighted-average rate of 12.0% |
|
| ( | ) |
Total operating lease liabilities |
| $ |
| |
The following table summarizes the supplemental cash flow information for the nine months ended September 30, 2026 and 2025:
|
| Nine Months Ended September 30, |
| |||||
|
| 2026 |
|
| 2025 |
| ||
Operating cash outflows from lease liabilities |
| $ |
|
| $ |
| ||
During the three and nine months ended September 30, 2026, we incurred rent expense of $
Duke License Agreement
The patented technology underlying 374Water’s supercritical water oxidation (SCWO) units was developed principally through the efforts of Kobe Nagar and Marc Deshusses at the facilities of Duke University, Durham, North Carolina (“Duke”), where Dr. Deshusses is a professor. The SCWO technology is licensed to 374Water pursuant to a worldwide license agreement with Duke executed on April 16, 2021 (the “Duke License Agreement”). In connection with the Duke License Agreement, 374Water also executed an equity transfer agreement with Duke pursuant to which Duke received common stock in the Company. Under the terms of the Duke License Agreement, the Company is required to make royalty payments based on a percentage of licensed product sales, as defined in the Duke License Agreement which is triggered by the sale of licensed products. Further, the Company is also required to pay royalties on a percentage of sublicensing fees. The Company will reimburse Duke for any ongoing patent expenses incurred. At September 30, 2026, the Company has not incurred any expenses in connection with this Duke License Agreement. The Company may terminate the license agreement at any time by providing Duke 60 days’ written notice.
Legal Matters
We note that in the ordinary course of business we may be the subject of, or party to, various pending or threatened legal actions which could result in a material adverse outcome for which the related damages may not be estimable. We do not believe any legal action would have a significant impact on the financials other than the matters disclosed below. However, there is inherent uncertainty regarding such matters.
On March 18, 2026, a stockholder class action complaint was filed with the Delaware Court of Chancery. The plaintiff seeks declaratory relief invalidating an exculpation provision contained in the Company’s Amended and Restated Certificate of Incorporation filed with the State of Delaware that purports to eliminate or limit the personal liability of the Company’s directors and officers beyond what is permitted under Delaware law. As disclosed in Note 7, on September 30, 2026, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the State of Delaware which amended and restated Article Eight, Section A of the Company’s certificate of incorporation relating to the personal liability of directors and officers, in order to conform such provision to Section 102(b)(7) of the General Corporation Law of the State of Delaware and addressed this complaint.
| 23 |
| Table of Contents |
On May 6, 2026, Peter Mandel, the Company's former General Counsel and consultant, filed a complaint against the Company in the United States District Court for the Northern District of California. The complaint asserts three causes of action: (i) breach of contract relating to the Separation and Release of Claims Agreement dated October 20, 2025 (the "Separation Agreement"), between Mr. Mandel and the Company; (ii) breach of contract relating to the Consulting Agreement dated October 9, 2025 (the "Consulting Agreement") between Mr. Mandel and the Company; and (iii) breach of the implied covenant of good faith and fair dealing.
The plaintiff alleges that the Company breached its contractual obligations by (a) failing to pay amounts owed under the Separation Agreement, including a pro-rated 2025 annual bonus; (b) failing to pay amounts owed under the Consulting Agreement; and (c) failing to issue, or cancelling, vested equity-based awards to which the plaintiff alleges he is entitled. The complaint seeks compensatory damages in an amount to be proven at trial, injunctive relief compelling the issuance of shares, costs of suit, and such other relief as the court may deem proper. The plaintiff has demanded a jury trial.
As of the date of these financial statements, all contractual amounts owed under the Separation and Consulting Agreements totaling approximately $
Complaint from Former Chief Financial Officer
On July 10, 2026, the Company received a demand letter and draft complaint from counsel for Russell Kline, the Company’s former Chief Financial Officer, whose employment terminated effective March 2, 2026.
Complaint from Former Chief Administrative Officer
In August 2026, Deborah Cooper, the Company’s former Chief of Staff and Chief Administrative Officer, filed a complaint against the Company in the Superior Court of the State of Delaware. The complaint asserts claims for breach of contract and, alternatively, unjust enrichment. It alleges that her March 2026 termination was without cause and that she is entitled to contractual severance, 2025 and pro-rated 2026 annual bonuses, accelerated vesting of certain equity awards, and delivery of shares underlying vested restricted stock units. She seeks unspecified damages, interest, and attorneys’ fees.
Employment Agreement with Chief Executive Officer
On April 27, 2026, the Company entered into an employment agreement (the “Employment Agreement”) with Daniel Bogar, the Company’s President and Chief Executive Officer. The Company’s appointment of Mr. Bogar as President and Chief Executive Officer, effective February 23, 2026, was previously reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2026.
The Employment Agreement provides that Mr. Bogar will receive an annual base salary of $
In addition,
Pursuant to the Company’s 2021 Equity Incentive Plan, as amended, the Company has granted Mr. Bogar:
Mr. Bogar will be eligible to participate in the Company’s employee retirement, insurance, benefit and paid time off programs on terms no less favorable than those provided to the Company’s other executive officers.
| 24 |
| Table of Contents |
If Mr. Bogar’s employment is terminated by the Company without “Cause” or by Mr. Bogar for “Good Reason” (each as defined in the Employment Agreement), and subject to his timely execution and non-revocation of a separation and release agreement in a form acceptable to the Company, Mr. Bogar will be entitled to receive: (i) an amount equal to six (6) months of his then-current base salary, payable in substantially equal installments over a six-month period in accordance with the Company’s regular payroll practices; (ii) continued coverage under the Company’s medical, health and vision insurance plans for Mr. Bogar and his eligible dependents for a period of six (6) months, subject to his continued payment of any required employee contribution; (iii) any earned but unpaid annual bonus with respect to any completed performance period or milestone; (iv) a pro-rated annual bonus for the fiscal year in which his employment terminates, based on actual performance, payable when annual bonuses are otherwise paid to other executives of the Company; and (v) accelerated vesting of the unvested portion of awards under the Company’s 2021 Equity Incentive Plan for a period of six (6) months following the termination date. Mr. Bogar will not be entitled to the foregoing severance benefits if he is removed as the Company’s President and Chief Executive Officer but is retained by the Company as an executive or senior officer with a base salary and bonus opportunity not reduced by more than ten percent (10%).
Employment Agreement with Chief Financial Officer
Effective July 1, 2026, the Company appointed Charles Weiser as its Chief Financial Officer (“CFO”). In connection with his appointment, Mr. Weiser and the Company entered into an employment agreement, dated as of July 1, 2026 (the “Weiser Employment Agreement”).
The Weiser Employment Agreement provides for an initial term commencing on July 1, 2026, subject to termination in accordance with its terms. Mr. Weiser will receive an annual base salary of $
Pursuant to the Company’s 2021 Equity Incentive Plan, as amended, Mr. Weiser was granted on July 1, 2026 (see Note 7):
Note 10 – Segment Reporting
Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer, Chief Operating Officer and Chief Financial Officer comprise the Company’s CODMs. The CODMs review financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. The CODMs use consolidated net income (loss) to assess performance, evaluate cost optimization, and allocate resources, including personnel-related and financial or capital resources, in the annual budget and forecasting process, as well as budget-to-actual variances on a monthly basis. As such, the Company has determined that it operates as one operating and reportable segment.
The significant expenses regularly reviewed by the CODMs are consistent with those reported on the Company's unaudited condensed consolidated statement of operations and expenses are not regularly reviewed on a more disaggregated basis for assessing segment performance and deciding how to allocate resources. The CODMs do not regularly review total assets for our single reportable segment as total assets are not used to assess performance or allocate resources.
Note 11 – Subsequent Events
The Company has evaluated subsequent events through the date on which the unaudited condensed consolidated financial statements were issued. Except as described below, no subsequent events were identified that would require adjustment to or disclosure in the unaudited condensed consolidated financial statements.
Convertible Notes
We issued five additional convertible notes under the same modified terms as discussed in Note 5 and received gross aggregate proceeds of $
Common Stock sold on the At-the-Market Offering
We sold an aggregate of
Settlement
See Note 9 for a settlement reached with our former in-house legal counsel who had filed a breach of contract complaint against the Company, subject to the negotiation of a definitive settlement agreement.
| 25 |
| Table of Contents |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with “Cautionary Note Regarding Forward-Looking Statements” and the financial statements and notes thereto appearing elsewhere in this Form 10-Q as well as the risk factors included in the 2025 Form 10-K.
Critical Accounting Policies
In preparing the condensed consolidated financial statements, we have made estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, costs, and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. Actual results may differ from these estimates. A summary of our critical accounting estimates and policies is included in our 2025 Form 10-K under "Management’s Discussion and Analysis of Financial Condition and Results of Operations."
During the three and nine months ended September 30, 2026, there have been no significant changes to these estimates and policies previously disclosed in our 2025 Form 10-K. For disclosure regarding recent accounting pronouncements and the anticipated impact they will have on our operations, please refer to Note 2 of the unaudited condensed consolidated financial statements included in this Form 10-Q.
Overview
374Water Inc. is a cleantech and environmental services company developing supercritical water oxidation (“SCWO”) for the destruction of organic waste streams within the municipal, federal, and industrial markets. 374Water offers our proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Importantly, our AirSCWO system is designed to eliminate recalcitrant organic wastes without creating waste byproducts, as well as to simplify existing, complex waste processing and disposal practices. Our AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including ‘forever chemicals’ (e.g., “per- and polyfluoroalkyl substances” or “PFAS”) into inert and recoverable resources including water, minerals, and heat energy.
| 26 |
| Table of Contents |
Results of Operations
The following table sets forth, for the periods presented, the consolidated statements of operations data, which is derived from the accompanying unaudited condensed consolidated financial statements:
Three Months Ended September 30, 2026, as Compared to the Three Months Ended September 30, 2025
|
| 2026 |
|
| 2025 |
|
| $ Change |
|
| % Change |
| ||||
Revenues |
| $ | 658,129 |
|
| $ | 760,417 |
|
| $ | (102,288 | ) |
|
| (13 | )% |
Cost of revenues |
|
| 339,910 |
|
|
| 547,785 |
|
|
| (207,875 | ) |
|
| (38 | )% |
Gross margin |
|
| 318,219 |
|
|
| 212,632 |
|
|
| 105,587 |
|
|
| 50 | % |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
| 282,481 |
|
|
| 755,944 |
|
|
| (473,463 | ) |
|
| (63 | )% |
Compensation and related expenses |
|
| 1,990,462 |
|
|
| 2,097,580 |
|
|
| (107,118 | ) |
|
| (5 | )% |
Professional fees |
|
| 233,643 |
|
|
| 257,228 |
|
|
| (23,585 | ) |
|
| (9 | )% |
General and administrative |
|
| 985,983 |
|
|
| 1,462,625 |
|
|
| (476,642 | ) |
|
| (33 | )% |
Total operating expenses |
|
| 3,492,569 |
|
|
| 4,573,377 |
|
|
| (1,080,808 | ) |
|
| (24 | )% |
Loss from operations |
|
| (3,174,350 | ) |
|
| (4,360,745 | ) |
|
| 1,186,395 |
|
|
| (27 | )% |
Total other income (expense), net |
|
| (86,859 | ) |
|
| 11,721 |
|
|
| (98,580 | ) |
|
| (841 | )% |
Loss before income taxes |
|
| (3,261,209 | ) |
|
| (4,349,024 | ) |
|
| 1,087,815 |
|
|
| (25 | )% |
Provision for income taxes |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 0 | % |
Net loss |
| $ | (3,261,209 | ) |
| $ | (4,349,024 | ) |
| $ | 1,087,815 |
|
|
| (25 | )% |
Revenues
Our business has been focused on the development and commercialization of our SCWO systems. During the three months ended September 30, 2026 and 2025, we generated revenue of $658,129 and $760,417, respectively, from equipment manufacturing and services, a decrease of approximately $102,000 due to higher value full-scale demonstrations in the prior period. Revenue for the three months ended September 30, 2026 consisted of approximately $610,000 of service revenue, including treatability studies, and approximately $48,000 of equipment revenue. The decrease is primarily due to a decrease in service revenue. Revenue for the three months ended September 30, 2025 consisted primarily of approximately $725,000 of service revenue from the completion of a full-scale demonstration and a bench-scale demonstration, and approximately $36,000 of equipment revenue.
Operating expenses
Our general and administrative expenses decreased to $985,983 during the three months ended September 30, 2026, as compared to $1,462,625 in the same period of 2025, a decrease of approximately $477,000, primarily due to a decrease in business travel costs of approximately $335,000, including reductions in Orlando-based employee reimbursable expenses in connection with our Orlando License Agreement that commenced February 2026, a decrease in investor relations expense of approximately $151,000, a decrease in stock-based compensation for services provided by the Board of Directors of approximately $79,000, and a decrease in other general and administrative expenses of approximately $35,000, partially offset by an increase in depreciation and rent expense of approximately $66,000 and $57,000, respectively.
Our compensation and related expenses decreased to $1,990,462 during the three months ended September 30, 2026, as compared to $2,097,580 in the same period of 2025, a decrease of approximately $107,000, primarily due to a decrease in stock-based compensation of approximately $337,000 and a decrease in salary and wage related expenses of approximately $70,000, offset by accrued severance expense of $300,000 related to complaints filed against the Company by our former Chief Financial Officer and Chief Administrative Officer.
Our professional fees decreased to $233,643 during the three months ended September 30, 2026, as compared to $257,228 in the same period of 2025, a decrease of approximately $24,000, primarily due to a decrease in consulting and recruiting fees of approximately $41,000 and $15,000, respectively, as the Company effectively ceased recruiting for new employees in early 2026, partially offset by an increase in stock-based compensation for consulting services of approximately $24,000 and an increase in professional services of approximately $9,000.
Our research and development expenses decreased to $282,481 during the three months ended September 30, 2026, as compared to $755,944 in the same period of 2025, a decrease of approximately $473,000, primarily due to the prior year incurring increased labor and contract labor to continue our efforts to commercialize and develop our systems. Due to cash flow constraints, external resources and contractors were utilized on a limited basis in 2026, resulting in a reduction of approximately $353,000. Further, there were cost reductions in our research and development payroll related expenses and stock-based compensation of approximately $84,000 and $36,000, respectively. The decrease in stock-based compensation is comprised of approximately $6,000 of stock-based compensation related to stock options and restricted stock units granted to our employees and approximately $30,000 of common stock issued for services to a consultant in the prior year period.
| 27 |
| Table of Contents |
Other income (expense), net
Other expenses, net was $86,859 during the three months ended September 30, 2026, as compared to other income, net of $11,721 in the same period of 2025, a change of approximately $99,000. This change is primarily due to an increase in interest expense of approximately $115,000 due to the issuance of convertible notes payable in 2026, partially offset by an increase in other income of approximately $16,000.
Net Loss
Our net loss decreased to $3,261,209 during the three months ended September 30, 2026, as compared to our net loss of $4,349,024 in the same period of 2025, a decrease of approximately $1,088,000. This change is primarily attributable to a decrease in operating expenses of approximately $1,081,000 as the Company focuses on reducing spending and managing expenses. Operating expenses decreased in all areas as more fully described above. Further, gross margin increased by approximately $106,000, partially offset by the increase in other expenses, net, as more fully described above.
Nine Months Ended September 30, 2026, as Compared to the Nine Months Ended September 30, 2025
|
| 2026 |
|
| 2025 |
|
| $ Change |
|
| % Change |
| ||||
Revenues |
| $ | 3,471,324 |
|
| $ | 1,898,484 |
|
| $ | 1,572,840 |
|
|
| 83 | % |
Cost of revenues |
|
| 821,720 |
|
|
| 1,823,935 |
|
|
| (1,002,215 | ) |
|
| (55 | )% |
Gross margin |
|
| 2,649,604 |
|
|
| 74,549 |
|
|
| 2,575,055 |
|
|
| 3,454 | % |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
| 1,016,904 |
|
|
| 1,820,701 |
|
|
| (803,797 | ) |
|
| (44 | )% |
Compensation and related expenses |
|
| 6,361,235 |
|
|
| 5,769,832 |
|
|
| 591,403 |
|
|
| 10 | % |
Professional fees |
|
| 900,615 |
|
|
| 1,678,467 |
|
|
| (777,852 | ) |
|
| (46 | )% |
General and administrative |
|
| 3,765,352 |
|
|
| 3,589,754 |
|
|
| 175,598 |
|
|
| 5 | % |
Total operating expenses |
|
| 12,044,106 |
|
|
| 12,858,754 |
|
|
| (814,648 | ) |
|
| (6 | )% |
Loss from operations |
|
| (9,394,502 | ) |
|
| (12,784,205 | ) |
|
| 3,389,703 |
|
|
| (27 | )% |
Total other income (expense), net |
|
| (1,134,565 | ) |
|
| 156,319 |
|
|
| (1,290,884 | ) |
|
| (826 | )% |
Loss before income taxes |
|
| (10,529,067 | ) |
|
| (12,627,886 | ) |
|
| 2,098,819 |
|
|
| (17 | )% |
Provision for income taxes |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 0 | % |
Net loss |
| $ | (10,529,067 | ) |
| $ | (12,627,886 | ) |
| $ | 2,098,819 |
|
|
| (17 | )% |
Revenues
Our business has been focused on the development and commercialization of our SCWO systems. During the nine months ended September 30, 2026 and 2025, we generated $3,471,324 and $1,898,484 in revenue from equipment manufacturing and services, respectively. This increase is primarily due to an increase in equipment sales revenue of approximately $1,792,000, driven by revenue recognized on our OC San contract that had been previously reversed or unrecognized due to variable consideration constraints that were eliminated upon us meeting a factory acceptance test during the nine months ended September 30, 2026, offset by a decrease in service revenues of approximately $218,000, as the prior year period included a greater number of higher-value full-scale demonstrations.
Operating expenses
Our general and administrative expenses increased to $3,765,352 during the nine months ended September 30, 2026, as compared to $3,589,754 in the same period of 2025, an increase of approximately $176,000, due to the expensing of approximately $184,000 of deferred offering costs previously capitalized on the balance sheet due to a shift in capital raise strategy through the issuance of convertible debt notes by the Company, an increase of approximately $243,000 in franchise tax expense due to the increase in our authorized shares, an increase of approximately $344,000 in stock-based compensation for services provided by the Board of Directors, and an increase of approximately $433,000 in depreciation, rent and insurance expense, offset by approximately $1,028,000 of reductions in other general and administrative expenses, primarily due to decreased business travel costs, including reductions in Orlando-based employee reimbursable expenses in connection with our Orlando License Agreement that commenced February 2026. As a result of the reduction in our authorized shares of common stock from 1,000,000,000 to 75,000,000 effective September 30, 2026, we expect our Delaware franchise tax expense to decrease in future periods.
| 28 |
| Table of Contents |
Our compensation and related expenses increased to $6,361,235 during the nine months ended September 30, 2026, as compared to $5,769,832 in the same period of 2025, an increase of approximately $591,000, primarily due to an increase in stock-based compensation of approximately $241,000 due to stock options granted to our employees during the nine months ended September 30, 2026 and equity-based compensation to our CEO and CFO pursuant to their employment agreements as well as an approximate $50,000 increase in payroll expenses primarily from bonuses to our newly hired CEO and CFO, and accrued severance expense of $300,000 related to complaints filed against the Company by our former Chief Financial Officer and Chief Administrative Officer.
Our professional fees decreased to $900,615 during the nine months ended September 30, 2026, as compared to $1,678,467 in the same period of 2025, a decrease of approximately $778,000, primarily due to a reduction in our recruiting fees of approximately $501,000 as the Company effectively ceased hiring new employees in early 2026 and incurred significant executive and director recruiting costs in the prior year period, an approximate reduction of $240,000 in legal fees, and an approximate reduction of $37,000 in other professional services related fees as the Company focuses on reducing expenses.
Our research and development expenses decreased to $1,016,904 during the nine months ended September 30, 2026, as compared to $1,820,701 in the same period of 2025, a decrease of approximately $804,000, primarily due to the prior year incurring increased equipment rental, labor, and contract labor to continue our efforts to commercialize and develop our systems. Further, stock-based compensation decreased by approximately $142,000, including approximately $90,000 of common stock issued for services to a consultant in the prior year period.
Other income (expense), net
Other expenses, net was $1,134,565 during the nine months ended September 30, 2026, as compared to other income, net of $156,319 in the same period of 2025, a change in other income (expenses), net, of approximately $1,291,000. This increase is primarily attributable to a loss on debt extinguishment recognized of approximately $1,022,000 during the nine months ended September 30, 2026 related to a modification of terms on outstanding convertible notes payable, as well as interest expense of approximately $218,000 recognized on the outstanding convertible notes payable issued in 2026 and a decrease in interest income of approximately $108,000, partially offset by an increase in other income of approximately $57,000.
Net Loss
Our net loss decreased to $10,529,067 during the nine months ended September 30, 2026, as compared to our net loss of $12,627,886 in the same period of 2025, a decrease of approximately $2,099,000. This change is primarily attributable to an increase in gross margin of approximately $2,575,000, driven by the OC San contract revenue recognized during the nine months ended September 30, 2026, and a decrease in operating expenses of approximately $815,000, partially offset by the increase in other expenses, net, of approximately $1,291,000, including the loss on debt extinguishment, as more fully described above.
Liquidity, Capital Resources and Going Concern
In accordance with ASU No. 2014-15 Presentation of Financial Statements – Going Concern (subtopic 205-40), the Company’s management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued. At September 30, 2026, the Company had a working capital of $501,008, an accumulated deficit of $60,465,665 and a cash balance of $266,116. For the nine months ended September 30, 2026, the Company incurred a net loss of $10,529,067 and used $4,154,268 of net cash in operations for the period. These conditions raise substantial doubt regarding our ability to continue as a going concern.
Presently, the Company will need additional debt or equity financing or a combination of both to continue its operations and meet its financial obligations for at least the next twelve months from the date these unaudited condensed interim consolidated financial statements included in this Form 10-Q were issued and beyond. We may consume available resources more rapidly than currently anticipated, resulting in the need for additional funding. We expect to incur continuing losses and negative cash flows from operations for the foreseeable future until we are able to manufacture our AirSCWO units on a commercial scale.
Since inception, we have financed our operations principally through the sale of debt and equity securities and operating cash flows. During the year ended December 31, 2025, we raised approximately $8,909,000 of net proceeds under our prior at-the-market equity offering program with Lake Street Capital Markets, LLC (“Lake Street”). During the nine months ended September 30, 2026, the Company issued convertible notes and received proceeds of $3,532,500. The convertible notes are secured by substantially all of our assets. As described in Note 5, the holders of the convertible notes waived and released any default arising from our nonpayment in cash of the interest due September 30, 2026 and elected either to convert such interest into shares of common stock or to defer its payment, and $80,112 of deferred interest is payable on March 31, 2027. Subsequent to September 30, 2026, we issued an additional $875,000 of convertible notes.
| 29 |
| Table of Contents |
We have entered into an at-the-market sales agreement (“ATM”), dated August 10, 2026 with Roberts & Ryan Inc. relating to shares of our common stock (the “Sales Agreement”). In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock, par value $0.0001 per share, having an aggregate offering price of up to $50,000,000 from time to time through Roberts & Ryan, acting as our sales agent.
This Sales Agreement replaces our prior sales agreement, dated December 23, 2025 with Lake Street (the “Prior Sales Agreement”) which replaced a prior sales agreement executed with Lake Street on June 6, 2025. The Company had no sales pursuant to the Prior Sales Agreement. No further sales will be made pursuant to the Prior Sales Agreement.
As of the date the prospectus was filed, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately $27,000,000, which was calculated based on 11,018,601 outstanding shares of the Company’s common stock held by non-affiliates at a price of $2.45 per share, the closing price of our common stock on June 11, 2026, as reported on Nasdaq. Pursuant to General Instruction I.B.6 of Form S-3, or the “baby shelf” rules, in no event will we sell securities registered on our Form S-3 registration statement, including under our ATM, with a value of more than one-third of the aggregate market value of shares of our common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of shares of our common stock held by non-affiliates is less than $75 million. During the three and nine months ended September 30, 2026, we sold 24,205 shares of our common stock for net proceeds of approximately $75,000.
Any additional debt or equity financing that the Company obtains may substantially dilute the ownership held by our existing stockholders. The economic dilution to our stockholders will be significant if our stock price does not materially increase, or if the effective price of any sale is below the price paid by a particular investor. The Company may be unable to access further equity or debt financing when needed or obtain additional financing under acceptable terms, if at all.
We may decide to raise additional capital through a variety of sources in the short-term and in the long-term, including but not limited to:
| ☐ | the public equity markets; |
| ☐ | private equity financings; |
| ☐ | collaborative arrangements; |
| ☐ | asset sales; and/or |
| ☐ | public or private debt. |
If the Company is unable to raise additional capital, there is a risk that the Company could be required to discontinue or significantly reduce the scope of its operations. These unaudited condensed interim consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Cash Flows
We used $4,154,268 of cash in operating activities for the nine months ended September 30, 2026 compared to $10,205,171 of cash used in operating activities for the corresponding period in 2025, a decrease of approximately $6,051,000. The decrease in cash used in operating activities was primarily due to a decrease in net loss of approximately $2,099,000, an increase in non-cash operating activities of approximately $1,872,000, primarily related to a loss on debt extinguishment of $1,022,000 and a $401,000 increase in stock-based compensation and approximately $2,080,000 increased cash inflows from changes in operating assets and liabilities.
| 30 |
| Table of Contents |
We used $1,452,868 in investing activities for the nine months ended September 30, 2026 compared to using $1,358,794 of cash in investing activities for the corresponding period in 2025, an increase of approximately $94,000. Cash used in investing activities for the nine months ended September 30, 2026 consisted of purchases of property and equipment of $1,452,868 compared to $1,358,794 in the previous period.
We received $2,674,570 of cash from financing activities for the nine months ended September 30, 2026 compared to $1,845,649 for the corresponding period in 2025. Cash provided by financing activities for the nine months ended September 30, 2026 primarily consisted of $3,532,500 of proceeds received from the issuance of convertible notes, offset by approximately $864,530 of repayments on debt obligations, including repayment of the $600,000 secured promissory note in January 2026. Cash provided by financing activities for the nine months ended September 30, 2025 primarily consisted of $1,911,096 of net proceeds from the sale of common stock under our ATM, $600,000 of proceeds from a secured promissory note and $24,000 of proceeds from a stock option exercise, offset by $649,980 for the repurchase of warrants and $39,467 of repayments on a note payable and financing liability.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
Not applicable.
Item 4. Controls and Procedures. Disclosure Controls and Procedures
The Company, under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company’s “disclosure controls and procedures” (as defined in Rule 13a-15(e)) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective due to the identified material weakness in the Company’s internal controls over financial reporting caused by the lack of full-time resources in our finance and accounting department. As a result of the identified material weakness, we are working to establish a remediation plan, which includes additional full-time personnel with the necessary skills and expertise to enhance the Company’s financial and accounting resources and control environment.
Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance of such reliability and may not prevent or detect misstatements. Also, projection of any evaluation of effectiveness to future periods is subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the three months ended September 30, 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 31 |
| Table of Contents |
PART II OTHER INFORMATION
Item 1. Legal Proceedings.
The information set forth under the “Legal Matters” section in Note 9 – Commitments and Contingencies in the notes to the unaudited condensed consolidated financial statements in Item 1 of Part I of this Form 10-Q is incorporated herein by reference.
Item 1A. Risk Factors.
See Item 1A. Risk Factors in the 2025 Form 10-K for a detailed discussion of risk factors affecting the Company. Except as set forth below, there have been no material changes in the risk factors disclosed in the 2025 Form 10-K.
Our convertible notes are secured by substantially all of our assets, and our failure to satisfy our obligations under the convertible notes could result in the loss of our assets.
As of September 30, 2026, we had $3,532,500 in aggregate principal amount of 10% convertible notes outstanding, which are secured by a security interest in substantially all of our assets. Due to cash flow constraints, we did not pay in cash the semi-annual interest due on September 30, 2026. Instead, each holder waived and released any default arising from such nonpayment and elected either to convert its accrued interest into shares of our common stock or to defer payment until March 31, 2027. We may not have sufficient cash to pay future interest, including the deferred interest, or principal when due, and the holders may not agree to similar accommodations in the future. If an event of default occurs under the convertible notes, the holders could accelerate the indebtedness and foreclose on our assets, which would have a material adverse effect on our business and could require us to curtail or cease operations.
If we fail to satisfy Nasdaq’s continued listing requirements, our common stock could be delisted.
Nasdaq Listing Rule 5550(b) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2.5 million, a market value of listed securities of at least $35 million, or net income from continuing operations of at least $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years. As of September 30, 2026, our stockholders’ equity was $641,468, and we have not reported net income from continuing operations. As a result, our continued compliance with this requirement depends on the market value of our listed securities remaining at or above $35 million, which will fluctuate with the trading price of our common stock. If we fail to satisfy this or any other continued listing requirement and are unable to regain compliance within any applicable cure period, our common stock could be delisted. Delisting could reduce the liquidity and market price of our common stock and impair our ability to raise capital, including under our at-the-market offering program and our Form S-3 registration statement.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The sales set forth below were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and, with respect to the convertible notes and related warrants, Rule 506(b) of Regulation D under the Securities Act, to investors who represented that they were accredited investors. Except as otherwise noted below, no placement agent fees or commissions were paid on these offerings, and net proceeds were used for working capital.
During the three months ended September 30, 2026, we issued $572,500 in aggregate principal amount of 10% secured convertible notes and received cash proceeds of the same amount.
The convertible notes bear interest at 10%, mature three years from the issue date and are convertible into shares of common stock at a conversion price of $3.00 per share and are secured by substantially all of the Company’s assets. Semi-annual interest payments are required on March 31 and September 30 of each year commencing September 30, 2026. The convertible notes include warrant coverage equal to the shares of common stock issuable upon the conversion of the note. Therefore, a total of 190,833 common stock warrants were issued to the convertible note holders during the three months ended September 30, 2026. The common stock warrants are exercisable immediately for a period of three years at an exercise price of $4.50 per warrant share.
On September 21, 2026, in connection with a release, strategic support and warrant issuance agreement with a stockholder, the Company issued a warrant to purchase 35,000 shares of common stock at an exercise price of $2.67 per share, exercisable for a period of five years. The warrant was issued in consideration of the stockholder’s release of claims and agreement to provide strategic support, and no cash proceeds were received.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
During the three months ended September 30, 2026, none of our directors or officers informed us of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K.
| 32 |
| Table of Contents |
Item 6. Exhibits.
(a) Exhibits
3.1 |
| Amended and Restated Certificate of Incorporation of Vyrex Corporation as filed with the Delaware Secretary of State on August 14, 2008 (previously filed on Form 10-Q for the quarter ended June 30, 2008, as filed with the SEC on August 19, 2008). |
|
|
|
3.2 |
| Certificate of Amendment of Certificate of Incorporation of PowerVerde, Inc. (previously filed on Form 10-K filed with the SEC on March 28, 2025). |
|
|
|
3.3 |
| Certificate of Amendment of Certificate of Incorporation of 374Water Inc. (previously filed on Form 8-K filed with the SEC on June 17, 2025). |
|
|
|
| 3.4 |
| Certificate of Amendment of Certificate of Incorporation of 374Water Inc. (previously filed on Form 8-K filed with the SEC on December 15, 2025). |
|
|
|
3.5 |
| Certificate of Amendment of Amended and Restated Certificate of Incorporation of 374Water Inc., as filed with the Delaware Secretary of State on September 30, 2026.* |
|
|
|
| 3.6 |
| Amended and Restated Bylaws of 374Water Inc., dated as of June 19, 2024 (previously filed on Form 8-K filed with the SEC on June 20, 2024). |
|
|
|
10.1 |
| Employment Agreement, dated April 27, 2026, by and between 374Water Inc. and Daniel Bogar (previously filed on Form 8-K with the SEC on May 1, 2026).+ |
|
|
|
10.2 |
| Employment Agreement, dated as of July 1, 2026, by and between 374Water Inc. and Charles Weiser (previously filed on Form 8-K filed with the SEC on July 8, 2026).+ |
|
|
|
| 31.1 |
| Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* |
|
|
|
| 31.2 |
| Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* |
|
|
|
| 32.1 |
| Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
|
|
|
| 32.2 |
| Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
|
|
|
| 101.INS |
| XBRL INSTANCE DOCUMENT |
|
|
|
| 101.SCH |
| XBRL TAXONOMY EXTENSION SCHEMA |
|
|
|
| 101.CAL |
| XBRL TAXONOMY EXTENSION CALCULATION LINKBASE |
|
|
|
| 101.DEF |
| XBRL TAXONOMY EXTENSION DEFINITION LINKBASE |
|
|
|
| 101.LAB |
| XBRL TAXONOMY EXTENSION LABEL LINKBASE |
|
|
|
| 101.PRE |
| XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE |
|
|
|
| 104 |
| Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). |
* Filed herewith.
** Furnished herewith.
+ Indicates a management contract, compensatory plan, or arrangement.
| 33 |
| Table of Contents |
SIGNATURES
In accordance with Section 13(a) or 15(d) of the Exchange Act, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
374WATER INC | |||
| Dated: November 16, 2026 | By: | /s/ Daniel Bogar | |
|
| Daniel Bogar | |
President and Chief Executive Officer | |||
|
|
|
|
Dated: November 16, 2026 | By: | /s/ Charles Weiser |
|
|
| Charles Weiser |
|
|
| Chief Financial Officer |
|
34 |